Cannabidiol is a Small Molecule owned by Radius Health, and is involved in 2 clinical trials, of which 1 was completed, and 1 is planned.

Cannabidiol acts as Cannabinoid Receptor 1 and 2 agonist. The drug candidate mimic the action of endocannabinoids and augment the effect in regulating the transmission of impulses from one nerve to another. Cannabinoid receptors (CB1/2) are responsible for proliferation, motility, invasion, adhesion, and apoptosis of cancer cells. The drug candidates thereby by agonizing cannabinoid receptors elicits therapeutic activity.

The revenue for Cannabidiol is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cannabidiol NPV Report.

Cannabidiol is currently owned by Radius Health.

Cannabidiol Overview

Cannabidiol is under development for the treatment of Angelman syndrome (AS). The drug candidate is administered through oral route as a solution. It was also under development for Lennox-Gastaut syndrome and Dravet syndrome. It was also under development for chemotherapy-induced peripheral neuropathy in taxol-treated patients, pediatric schizophrenia, pontine glioma, infantile spasms, autism, unspecified indication, pediatric epilepsy (childhood absence seizures), Prader-Willi syndrome and glioblastoma.

Radius Health Overview

Radius Health, formerly NuVios Inc, is a biopharmaceutical company that develops and markets novel medicines for bone health, and endocrine diseases. The company’s marketed product includes abaloparatide injection, which is indicated for the treatment of postmenopausal women with osteoporosis. Its pipeline encompasses abaloparatide subcutaneous injection (SC) for high risk of fracture in men with osteoporosis; abaloparatide transdermal (TD) patch for postmenopausal women with osteoporosis; elacestrant (RAD1901) for estrogen-receptor (ER)-positive breast cancer; and RAD140 as an oral treatment for triple-negative, ER-positive, and ER-negative breast cancers. The company operates in Parsippany, Wayne, and Cambridge in the US. Radius Health is headquartered in Boston, Massachusetts, the US. Radius Health, formerly NuVios Inc, is a biopharmaceutical company that develops and markets novel medicines for bone health, and endocrine diseases. The company’s marketed product includes abaloparatide injection, which is indicated for the treatment of postmenopausal women with osteoporosis. Its pipeline encompasses abaloparatide subcutaneous injection (SC) for high risk of fracture in men with osteoporosis; abaloparatide transdermal (TD) patch for postmenopausal women with osteoporosis; elacestrant (RAD1901) for estrogen-receptor (ER)-positive breast cancer; and RAD140 as an oral treatment for triple-negative, ER-positive, and ER-negative breast cancers. The company operates in Parsippany, Wayne, and Cambridge in the US. Radius Health is headquartered in Boston, Massachusetts, the US.

Quick View – Cannabidiol

Report Segments
  • Innovator
Drug Name
  • Cannabidiol
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Oncology
  • Toxicology
  • Undisclosed
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.